Time  (AM Dose)                                                                         (PM Dose)

-60

-30

+60

+120

-30

+60

+120

+180

+240

HEART RATE
Plc/Plc
69.78 (9.27)

Plc/SYN115
72.85 (11.26)



67.0 (10.81)


72.30 (9.97)



63.0 (9.29)


65.69 (7.21)



60.56 (6.56)


63.38 (4.86)



62.22 (9.74)


64.76 (6.49)


65.22 (8.97)


63.85 (8.16)


62.78 (8.21)


62.76 (6.15)


64.0 (7.94)


66.15 (7.82)


61.44 (4.95)


65.23 (4.75)

SYSTOLIC BP (mm Hg)
Plc/Plc
111.89 (10.09)

Plc/SYN115
108.77 (10.84)




112.56 (10.44)

108.08 (11.84)




112.22 (11.19)

114.69 (12.73)




111.67 (13.71)

115.15 (9.05)




113.0 (11.32)

112.15 (8.59)




111.56 (5.48)

111.92 (9.21)




107.0 (5.41)

113.38 (11.38)



114.11 (13.46)

116.84 (12.44)



121.33 (13.9)

122.0 (17.1)

DIASTOLIC BP (mm Hg)
Plc/Plc
72.89 (10.95)

Plc/SYN115
71.54 (11.12)


73.11 (7.08)

72.15 (10.67)




69.67 (8.08)

73.76 (12.28)




70.56 (11.40)

73.23 (9.81)




72.67 (12.35)

74.54 (6.84)




77.22 (4.02)

76.54 (6.41)



73.56 (5.75)

75.85 (11.30)




67.22 (8.30)

75.76 (9.82)




73.33 (6.81)

76.77 (10.83)

Table 1: Pre- and post-dose measures of heart rate, systolic and diastolic blood pressure across two groups of dosing conditions (Placebo AM / Placebo PM, 9 subjects = Plc/Plc) or (Placebo AM / SYN115 PM, 13 subjects = Plc/SYN115). Data show means (± SD). There were no statistically significant differences between dose conditions.